NCT02299336View on ClinicalTrials.gov

Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 24, 2014

Primary Completion Date

January 9, 2017

Study Completion Date

January 9, 2017

Conditions

Diabetic Macular Edema

Interventions

DRUG

Aflibercept

pro re nata (PRN)

PROCEDURE

Focal Laser

Focal laser administered based on pre-specified criteria

Trial Locations (3)

77030

Retina Consultants of Houston/The Medical Center, Houston

77384

Retina Consultants of Houston, The Woodlands

77494

Retina Consultants of Houston/Katy office, Katy

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Greater Houston Retina Research

OTHER

NCT02299336 - Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial | Biotech Hunter | Biotech Hunter